Laurus Labs Steps Up Inorganic Bets With Fresh Investments In Laurus Bio And KRKA Pharma

Laurus Labs Limited has announced two strategic capital allocations aimed at strengthening its biologics and formulations platforms. The company has made an additional investment of Rs 349.88 crore in its subsidiary Laurus Bio Private Limited via subscription to Series A3 compulsorily convertible preference shares on a private placement basis, taking its fully diluted holding in Laurus Bio to 75.61%.

Separately, Laurus Labs has invested Rs 49 crore in KRKA Pharma Private Limited, its joint venture with Slovenia based KRKA d.d., by subscribing to 4.9 crore equity shares of face value Rs 10 each through a rights issue, with no change in the existing JV shareholding structure. The fresh funds are expected to support ongoing capex and future manufacturing capacity at the JV, complementing Laurus Labs’ broader expansion plans in formulations and CDMO businesses. 
​
Key Highlights

• Additional Rs 349.88 crore infused into Laurus Bio through Series A3 compulsorily convertible preference shares on preferential basis.
• Post‑investment, Laurus Labs’ stake in Laurus Bio rises to 75.61% on a fully diluted basis, consolidating control over its biotech arm. 
• Rs 49 crore invested in KRKA Pharma JV via rights issue at Rs 10 per share, with Laurus subscribing to 4.9 crore equity shares. 
• ​Shareholding pattern in KRKA Pharma remains unchanged, with KRKA d.d. and Laurus Labs continuing to hold 51% and 49% respectively.
• ​Investments align with Laurus Labs’ ongoing multi‑year capex programme to scale biologics, CDMO and finished dosage capabilities and to capture emerging market opportunities.

​
Sources: BSE India corporate filings for Laurus Labs; Laurus Labs Limited